Publications

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Poster presented at the EADV Congress 2023, Berlin, Germany.

Poster presented at the EADV Congress 2023, Berlin, Germany.

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Oral presentation presented at the conference of the European Society for Dermatology and Psychiatry (ESDaP), Rotterdam, the Netherlands

Evaluation of patient-reported outcomes including health-related quality of life (HRQoL) and perceived benefits from treatment has become a fundamental component of medical decision-making. Standardized evaluation of treatment benefits in rosacea based on patient preferences is still lacking.

Development and validation of an instrument for recording patient-defined benefits in rosacea therapy based on the Patient Benefit Index (PBI) methodology.

In an open survey of n = 50 patients, potential benefits of therapy from the patient’s perspective were examined. The generated item pool was combined with pre-existing PBI items for other skin conditions and reviewed by an expert panel of dermatologists, psychologists and patients. Items were condensed to n = 25 and converted into a Likert-scaled questionnaire. The validity and feasibility of the resulting Patient Benefit Index for rosacea (PBI-RO) were tested on individuals with rosacea recruited from a German rosacea patient organization.

N = 446 patients with rosacea completed the PBI-RO. The internal consistencies measured by Cronbach’s alpha were high (Patient Needs Questionnaire [PNQ] 0.94). Mean PBI-RO was 1.9 ± 1.2 (scale from 0 = no benefit to 4 = maximum benefit), 23.5% of the patients experienced a PBI-RO < 1 (no clinically relevant benefit). The PBI-RO correlated with HRQoL, health state, current extent of rosacea lesions and treatment satisfaction. The highest correlation was found between PBI-RO and satisfaction with previous treatment (r = −0.59, p < 0.001); correlation with the extent of rosacea lesions was low (r = 0.16, p < 0.001).

The PBI-RO shows satisfying internal consistency and construct validity. It offers the option of a patient-weighted evaluation of the therapeutic benefit of rosacea therapy and may add to more stringent goal orientation in therapy.

The value of psychological principles has become apparent in medical settings, especially with the rise of patient-centered care. We aimed to provide a curriculum informing medical providers about the theoretical basis and clinical utility of the social-cognitive model of stress and coping.

Patient-relevant benefits from treatment of inflammatory skin diseases can be measured with the validated 25-item questionnaire Patient Benefit Index Standard version (PBI-S; www.patient-benefit-index.com). It consists of two parts: the Patient Needs Questionnaire, in which patients rate the importance of 25 different treatment goals, and the Patient Benefit Questionnaire, in which patients evaluate the achievement of these goals by therapy. From all items, an importance-weighted total benefit score is determined. However, shorter instruments are often preferable both in practice and in clinical trials. We therefore developed and tested a 10-item short form of the PBI-S named the ‘PBI-S-10’, which should maintain both content validity and good psychometric properties. The short form should allow for the calculation of a total score that indicates overall patient-relevant benefit and demonstrate high agreement with the long form.

Poster presented at the DKVF Conference, Potsdam, Germany